期刊
TRANSFUSION AND APHERESIS SCIENCE
卷 54, 期 3, 页码 345-355出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.transci.2016.05.011
关键词
DLI; Allogeneic transplantation; Relapse; Pre-emeptive; Hematological disease
类别
Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use. (C) 2016 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据